Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00271232 · ClinicalTrials.gov registry record · NA
InSync III Marquis Model 7279 Cardioverter Defibrillator Cardiac Resynchronization System
A NA study of Heart Failure, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- NA
- Development phase
- 238
- Enrollment target
- 20
- Study locations
NCT00271232: Completed NA study of Heart Failure, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
NCT00271232 is a NA study of Heart Failure that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 238 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00271232, a NA study of Heart Failure, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- NA
- Development phase
- 238 participants
- Enrollment target
- 20
- Study locations
Study Summary
People who have a dangerously fast heart beat, or whose heart is at risk of stopping beating, may be in need of an electronic device called an implantable cardioverter defibrillator (ICD). An ICD is implanted surgically just under the skin in the upper chest area and it sends a strong electrical impulse, or shock, to the heart to return it to a normal rhythm. If the heart is beating too slowly or at an abnormal rhythm, an ICD can also pace the heart to return the heart to its normal rhythm. The InSync III Marquis device can change the timing of when the left and right ventricles of the heart are paced to beat. This is called "V to V timing". V to V timing may further improve the pumping function of the heart. The purpose of this study is to determine whether or not this V to V timing feature of the InSync III Marquis system is safe and effective.
Conditions Studied
Interventions
- DEVICE Cardiac resynchronization therapy
Study Locations (20)
Florida
- - Jacksonville
- - Pensacola
- - Tampa
New York
- - New York
- - Rochester
- - Syracuse
California
- - Los Angeles
- - Stanford
Minnesota
- - Minneapolis
- - Saint Paul
Alaska
- - Anchorage
Arizona
- - Phoenix
Georgia
- - Atlanta
Indiana
- - Beech Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2003-03 |
| Est. Completion | 2005-04 |
| Phase | NA |
What the finished NCT00271232 record still lists
NCT00271232 is an interventional study that assigns participants to a tested intervention. The registered 238 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Cardiac resynchronization therapy is the first listed.
NCT00271232 names 20 study sites across 14 states, led by Florida, New York, California.
Frequently Asked Questions
What is clinical trial NCT00271232 about?
NCT00271232 is a clinical study titled "InSync III Marquis Model 7279 Cardioverter Defibrillator Cardiac Resynchronization System". People who have a dangerously fast heart beat, or whose heart is at risk of stopping beating, may be in need of an electronic device called an implantable cardioverter defibrillator (ICD). An ICD is implanted surgically just under the skin in the upper chest area and it sends a strong electrical imp...
What is the current status of trial NCT00271232?
This trial is currently completed. It is a NA study. The enrollment target is 238 participants. The study started on 2003-03. Estimated completion is 2005-04.
What conditions does trial NCT00271232 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT00271232?
The interventions under investigation include: Cardiac resynchronization therapy (DEVICE).
Who is sponsoring clinical trial NCT00271232?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00271232 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00271232's enrollment target sits among peer trials
238 153rd of 397 higher than 245 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05012072 · 238 participants · NA
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
- NCT05400252 · 238 participants · NA
Whole Health in VA Mental Health: Omnis Salutis
- NCT06380517 · 238 participants · Phase 3
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
- NCT06452797 · 238 participants · NA
Prognostic Estimates Among ICU Clinicians
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia